



MT2021-25: Phase I/II Multicenter study evaluating the Safety and Efficacy of Allogeneic GDA-201 Natural Killer cells in patients with relapsed/refractory B-Cell Non-Hodgkin Lymphoma

Status: Recruiting

Eligibility Criteria

Conditions & Interventions

Keywords:

Clinics and Surgery Center (CSC)

More Information

Description: This study is designed to assess the safety of GDA-201 + rituximab, as well as the maximum tolerated dose in patients with B cell lymphomas in phase I; in phase II, it will assess safety and efficacy of GDA-201 in cohorts of patients with follicular lymphoma, high grade B cell lymphoma (including diffuse large B-cell), high grade B cell lymphoma not otherwise specified, and primary mediastinal B cell lymphoma.

Contact(s): Veronika Bachanova - bach0173@umn.edu Principal Investigator: Veronika Bachanova, MD

IRB

Number: STUDY00015044

System ID: 35762

Thank you for choosing StudyFinder. Please visit http://studyfinderstaging.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.